- April 26, 2022
- Newsletter
- 617-430-5616
Menu
» Home » CAD » Oncology » Hematology » Non-Hodgkin’s Disease
ADVERTISEMENT
ADVERTISEMENT
» Home » CAD » Oncology » Hematology » Non-Hodgkin’s Disease
Background
Epidemiology
Anatomy
Pathophysiology
Etiology
Genetics
Prognostic Factors
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
150 - 200
mg/m^2
Intravenous (IV)
as a single dose for at least six weeks
Or divided into daily injections as a dose of 75-100 mg/m2 given IV for every two days
50
mg/m^2
Intravenous (IV)
on day 1 every 21 days in combination with cyclophosphamide, vincristine, and prednisone.
Dosimetric dose:
450
mg
Intravenous (IV)
infuse over 1 hour
next I-131 tositumomab five mCi I-131 + 35 mg protein Intravenous (IV) infusion for 20 minutes
Therapeutic dose:
450 mg Intravenous (IV) infuse over 1 hour, next I-131 tositumomab dose determined to produce 75 cGy total body irradiation for patients with average platelet count 7 -14 days after a dosimetric dose
25
mg/m^2
Intravenous (IV)
per day infused over 1 hour on days 4 and 5 of a 21- to 28- day cycle in combination with cyclophosphamide, prednisone, methotrexate, and vincristine (dose adjustment may depend on neutrophil recovery).
Future Trends
References
ADVERTISEMENT
» Home » CAD » Oncology » Hematology » Non-Hodgkin’s Disease
150 - 200
mg/m^2
Intravenous (IV)
as a single dose for at least six weeks
Or divided into daily injections as a dose of 75-100 mg/m2 given IV for every two days
50
mg/m^2
Intravenous (IV)
on day 1 every 21 days in combination with cyclophosphamide, vincristine, and prednisone.
Dosimetric dose:
450
mg
Intravenous (IV)
infuse over 1 hour
next I-131 tositumomab five mCi I-131 + 35 mg protein Intravenous (IV) infusion for 20 minutes
Therapeutic dose:
450 mg Intravenous (IV) infuse over 1 hour, next I-131 tositumomab dose determined to produce 75 cGy total body irradiation for patients with average platelet count 7 -14 days after a dosimetric dose
25
mg/m^2
Intravenous (IV)
per day infused over 1 hour on days 4 and 5 of a 21- to 28- day cycle in combination with cyclophosphamide, prednisone, methotrexate, and vincristine (dose adjustment may depend on neutrophil recovery).
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.